Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinβ1 and its related pathway

Toxicology and Applied Pharmacology

Volumn 259, Issue 3, 2012, Pages 387-394

  Zhu, Binbin ^a   Zhao, Li ^a   Zhu, Litao ^a   Wang, Hu ^a   Sha, Yunying ^a   Yao, Jing ^a   Li, Zhiyu ^a   You, Qidong ^a   Guo, Qinglong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

CAM DR; Fibronectin; Integrin 1; Oroxylin a

Indexed keywords

BETA1 INTEGRIN; FIBRONECTIN; FOCAL ADHESION KINASE; OROXYLIN A; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; SCUTELLARIAE RADIX; SURVIVIN;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL STRAIN HEPG2; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VITRO STUDY; PROTEIN EXPRESSION; UPREGULATION;

ANTIGENS, CD29; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PACLITAXEL; SCUTELLARIA BAICALENSIS;

SCUTELLARIA RADIX;

EID: 84862817427     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.01.019     Document Type: Article

References (29)

1. Aoudjit F., Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001, 20:4995-5004.
2. Dalton W.S. The tumor microenvironment: focus on myeloma. Cancer Treat. Rev. 2003, 29(Suppl 1):11-19.
3. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93:1658-1667.
4. Duffy M.J., McGowan P.M., Gallagher W.M. Cancer invasion and metastasis: changing views. J. Pathol. 2008, 214:283-293.
5. Durand R.E., Sutherland R.M. Effects of intercellular contact on repair of radiation damage. Exp. Cell Res. 1972, 71:75-80.
6. Fojo T., Bates S. Strategies for reversing drug resistance. Oncogene 2003, 22:7512-7523.
7. Gilmore A.P., Metcalfe A.D., Romer L.H., Streuli C.H. Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. J. Cell Biol. 2000, 149:431-446.
8. Guan J.L. Focal adhesion kinase in integrin signaling. Matrix Biol. 1997, 16:195-200.
9. Hazlehurst L.A., Enkemann S.A., Beam C.A., Argilagos R.F., Painter J., Shain K.H., Saporta S., Boulware D., Moscinski L., Alsina M., Dalton W.S. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003, 63:7900-7906.
10. Hazlehurst L.A., Landowski T.H., Dalton W.S. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 2003, 22:7396-7402.
11. Hazlehurst L.A., Valkov N., Wisner L., Storey J.A., Boulware D., Sullivan D.M., Dalton W.S. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 2001, 98:1897-1903.
12. Hu Y., Yang Y., You Q.D., Liu W., Gu H.Y., Zhao L., Zhang K., Wang W., Wang X.T., Guo Q.L. Oroxylin A induced apoptosis of human hepatocellular carcinoma cell line HepG2 was involved in its antitumor activity. Biochem. Biophys. Res. Commun. 2006, 351:521-527.
13. Khwaja A., Rodriguez-Viciana P., Wennstrom S., Warne P.H., Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 1997, 16:2783-2793.
14. Kumar C.C. Signaling by integrin receptors. Oncogene 1998, 17:1365-1373.
15. Landowski T.H., Olashaw N.E., Agrawal D., Dalton W.S. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 2003, 22:2417-2421.
16. Li H.B., Chen F. Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J. Chromatogr. A 2005, 1074:107-110.
17. Li Z.W., Dalton W.S. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev. 2006, 20:333-342.
18. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
19. Meredith J.E., Fazeli B., Schwartz M.A. The extracellular matrix as a cell survival factor. Mol. Biol. Cell 1993, 4:953-961.
20. Mudry R.E., Fortney J.E., York T., Hall B.M., Gibson L.F. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000, 96:1926-1932.
21. Sethi T., Rintoul R.C., Moore S.M., MacKinnon A.C., Salter D., Choo C., Chilvers E.R., Dransfield I., Donnelly S.C., Strieter R., Haslett C. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 1999, 5:662-668.
22. Shain K.H., Dalton W.S. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol. Cancer Ther. 2001, 1:69-78.
23. Shain K.H., Landowski T.H., Dalton W.S. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol. 2002, 168:2544-2553.
24. St Croix B., Sheehan C., Rak J.W., Florenes V.A., Slingerland J.M., Kerbel R.S. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J. Cell Biol. 1998, 142:557-571.
25. Sun Y., Lu N., Ling Y., Gao Y., Chen Y., Wang L., Hu R., Qi Q., Liu W., Yang Y., You Q., Guo Q. Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Eur. J. Pharmacol. 2009, 603:22-28.
26. Yang H.Y., Zhao L., Yang Z., Zhao Q., Qiang L., Ha J., Li Z.Y., You Q.D., Guo Q.L. Oroxylin a reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-kappaB signaling pathway. Mol. Carcinog. 2011.
27. Yang Y., Hu Y., Gu H.Y., Lu N., Liu W., Qi Q., Zhao L., Wang X.T., You Q.D., Guo Q.L. Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells. J. Pharm. Pharmacol. 2008, 60:1459-1463.
28. Zhang H.W., Yang Y., Zhang K., Qiang L., Yang L., Hu Y., Wang X.T., You Q.D., Guo Q.L. Wogonin induced differentiation and G1 phase arrest of human U-937 leukemia cells via PKCdelta phosphorylation. Eur. J. Pharmacol. 2008, 591:7-12.
29. Zhao L., Chen Z., Wang J., Yang L., Zhao Q., Qi Q., Mu R., You Q.D., Guo Q.L. Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemother. Pharmacol. 2010, 65:481-489.